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Several clinical trials aimed at the induction of antitumour reactivity
via vaccination against tumour-associated antigens, gp100,
MAGE3, CEA, are ongoing (Marchand et al, 1995; Rosenberg et al,
1998; Morse et al, 1999). It is very important to search for tumour
antigens which are widely expressed targets for CTLs restricted to
major histocompatibility complex (MHC) class I for the develop-
ment of T cell-mediated immunotherapy of cancer (Vierboom et al,
1997). The gastrointestinal adenocarcinomas are very common and
a number of patients die of various kinds of adenocarcinomas.
Therefore, the antigens expressed in adenocarcinomas are expected
targets for immunotherapy. The p53 is expressed in tumour cells of
50% of patients with cancer (Harris, 1996). Regarding gastro-
intestinal adenocarcinoma, the p53 expression was shown to be
relatively high compared with that observed in other tumours. p53
overexpression is observed in 62% of oesophageal squamous cell
carcinoma, 50–60% of gastric carcinoma, 55% of colon carcinoma,
50–60% of pancreatic carcinoma, and 58% of gall bladder carci-
noma (Campo et al, 1991; Wever, 1998). It has been clarified that
p53 serves as a target for immunorecognition and in fact, Deleo et al
initially identified p53 as a tumour antigen (Deleo et al, 1979).
Recently, p53 was identified as a tumour antigen and p53 epitope
peptides as suitable for presentation by HLA molecules (Yanuck 
et al, 1993; Theobold et al, 1995; Mayordomo et al, 1996; Theobald
et al, 1997; Gnjatic et al, 1998; Chikamatsu et al, 1999). These
immunoresponses are generally linked to the mutations of the p53
gene that result in the accumulation of dysfunctional p53 product in
the nucleus or cytoplasm of tumour cells (Ropke et al, 1996; Roth
et al, 1996; Yu et al, 1997; McCarty et al, 1998; Theobald et al,
1998; Schawarz et al, 1999). Since the defects in overexpressed p53
are mostly caused by point mutations, the majority of the wild-type
epitopes appeared to be conserved. Therefore, the overexpressed
and non-mutated epitopes could be the immunotherapeutic targets
for cytolytic response in most of the patient population. 
The HLA-A2 restricted CTL-inducing peptides have been
reported in the non-mutated region of wild-type p53. Todd et al
reported that HLA-A*0201 restricted murine CTL lines specific to
epitope 149–157 of p53 suppressed the growth of established
tumours in vivo (Yanuck et al, 1993). Gnjatic et al showed that
CTL lines recognizing p53 epitope 264–272 kill the breast carci-
noma cells and the melanoma cells displaying the accumulated
p53 protein (Gnjatic et al, 1998). However, the tumour rejection
peptides that are restricted by HLA-A24 have not been identified
yet. Since HLA-A24 is one of the most popular HLA alleles in
Japanese (>60%) and also in Caucasians (Kubo et al, 1994), it
appears to be important to find such peptides if it exists. 
CTL epitopes from numerous TAA have been identified by
multiple methods (Celis et al, 1994). In this study, p53-derived cyto-
toxic peptides were predicted from murine p53-derived cytotoxic
peptides which were presented to CTL by H-2Kd and H-2Kb mole-
cules, since binding motifs of the HLA-A24 peptide are similar to
those of H-2Kd and H-2Kb. We predicted 3 peptides, and then tested
their capacity to bind to HLA-A24 molecules. This study shows that
one of them can induce tumour reactive CTL responses in vitro from
PBMC of HLA-A24 positive healthy volunteers in vitro. 
MATERIALS AND METHODS 
Cell lines 
The TISI cells, human B lymphoblastoid cell lines expressing
HLA-A*2402, were used for peptide-mediated cytotoxic assays.
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The CIR cells are HLA-A,B null cells (HLA-C; weakly positive).
The C1R-A24 cells are the C1R cells transfected with HLA-
A*2402 gene. The C1R and C1R-A24 cells were kindly provided
by Dr Takiguchi (University of Kumamoto, Japan). HT29(HLA-
A24/1), colon carcinoma cell line, and NKN45(HLA-A24/24),
gastric carcinoma cell line, were provided by Takara Shuzo Co,
Ltd. (Otsu, Japan). PC9 (HLA-A24/2), lung adenocarcinoma cell
line was kindly provided by Dr Yasumoto (University of
Occupational and Environmental Health, Japan). These cell lines
were maintained in a tissue cultureflask using RPMI 1640 supple-
mented with HEPES, antibiotics, and 10% heat-inactivated fetal
bovine serum (FBS) (Gibco, BRL). The accumulation of p53 in all
the cell lines in this study was analysed using immunohistochem-
istry. The p53 was accumulated in HT29, PC9 and C1R-A24 cells.
However, expression of p53 was not detected in MKN45, and TISI
cells. The mutation-analysis of p53 (exons 5–8) was performed on
HT29, MKN45, PC9, C1R-A24 and TISI cell lines using single
strand conformation polymorphism (SSCP) and direct sequence
analysis. These results are summarized in Table 1. 
Synthesis of p53-derived peptides 
Peptides were synthesized according to the standard solid phase
synthesis method and purified by reversed phase high performance
liquid chromatography (HPLC). The purity (>97%) and the iden-
tity of the peptides were determined by analytical HPLC and mass
spectrometry analysis, respectively. Peptides were dissolved in
dimetilsulphoxide (DMSO) at 20 mg ml–1 and stored at –30˚C. 
MHC binding assay by flowcytometry 
The binding affinity of the peptides for HLA-A24 molecules was
examined using C1R-A24 cells. A total of 1 ´ 106 cells were
washed 2 times in phosphate buffered saline (PBS) to remove
contaminating calf serum proteins. Peptides binding to HLA-A24
molecules on C1R-A24 were stripped by mild acid treatment with
an ice cold citrate phosphate buffer (0.131 M citric acid and
0.066 M Na2HPO4) (Stomkus et al, 1993). The buffer was adjusted
to pH 3.3 with 5N NaOH or 5N HCl; this pH is essential for
optimal elution of bound peptides and reconstitution of MHC class
1 molecule with the exogenously added peptides. Two millilitres
of citrate phosphate buffer were added, and cell pellets were resus-
pended with gentle hand rocking for 60 s. Immediately after incu-
bation, the eluted cells were buffered with a cold serum-free
medium, and washed twice. Residual medium was removed by
aspiration after the wash. To load the synthetic peptides, the C1R-
A24 cells were incubated with 20 mgm l –1 of synthetic peptides for
2 h at 4˚C. After the washing, the expression levels of MHC class
1 molecules were determined by flowcytometric analysis using an
anti class 1 antibody (W6/32) (Immunotec, Marseille, France). 
Primary CTL induction cultures 
Monocyte-derived DCs were used as antigen-presenting cells
(APC) to trigger CTL responses using an MHC binding peptide.
DCs were generated in vitro as described previously (Romani et al,
1994) (Romani and Gruner, 1994; Nukaya et al, 1999). Briefly,
PBMCs isolated from a normal volunteer (HLA-A24) by Ficoll-
Paque (Pharmacia, Piscataway, NJ) were separated by adherence
to a plastic tissue culture flask to enrich the monocyte fraction.
The monocyte-enriched population was then cultured in the
presence of 1000 U ml–1 of granulocyte macrophage colony
stimulating factor (GM-CSF) (Genzyme) and 2000 U ml–1 IL-4
(Genzyme) in RPMI 1640 containing HEPES and supplemented
with 2 mM of L-glutamine, 1 mM of sodium pyruvate and 0.1 mM
of non- essential amino acid solution, 5% heat–inactivated AB
human serum (HS) (all reagents from BioWhittakar, Walkersville,
MD), and antibiotics (RPMI/5% HS). After 7 days in the culture,
generated DC was pulsed with 40 mgm l –1 of MHC-binding
peptides in the presence of 3 mg ml–1 of b2-microglobulin for 4 h at
20˚C in phosphate-buffered saline (PBS) containing 1% bovine
serum albumin. The peptide-pulsed DC was then irradiated (5500
rad) and mixed at a 1:20 ratio with autologous CD8+ T cells,
obtained by positive selection using Dynabeads M-450 CD8
(Dynal, Lake Success, NY) and Detachabead (Dynal) following
manufacturer’s protocol. These cultures were set up in 48-well
plates; each well contained 0.25 ´ 105 peptide-pulsed DC, 5 ´ 105
CD8+ cells and 10 ng ml–1 IL-7 (Genzyme) in 0.5 ml of RPMI/5%
HS. One day later, the CTL cultures were supplemented with 
IL-10 (R&D Systems, Minneapolis, MN) to a final concentration
of 10 ng ml–1. On days 7 and 14, the T cell cultures were restimu-
lated with autologous peptide-pulsed adherent APC. To prepare
the adherent APC, 2 ´ 106 irradiated autologous PBMC in 0.5 ml
of RPMI/5% HS was added to each well of 48-well plates. After
incubation at 37˚C for 90 min, the non-adherent cells were washed
off, and the adherent cells were incubated for 2 h with 20 mgm l –1
of peptide and 3 mgm l –1 b2- microglobulin in a final volume of
0.25 ml of RPMI/5% HS per well. Supernatants of the responder
cultures were aspirated and RPMI/5% HS was added to the total
volume of 0.5 ml well–1. After removing the un-loaded peptide
from the wells of adherent APC, the responder cultures were trans-
ferred to the corresponding wells containing peptide-pulsed APC.
Each well was restimulated separately and on the day following
each restimulation, a final concentration of 10 ng ml–1 of IL-10
was added to each culture. The cultures were fed every 2–3 days
with RPMI/5% HS containing 10 U ml–1 of IL-2 (Shionogi, Osaka,
Japan). Cytotoxic activity was tested after 2 and 4 rounds of
peptide stimulation on days 21 and 36 using peptide-pulsed TISI
cells. Responder cells in positive wells for peptide killing were
expanded as described below and tested for their cytotoxity. 
CTL assay 
The tumour cells used as targets in the cytotoxicity assays were
cultured as described previously in the presence of IFN–g (100 U
ml–1) to enhance the expression of MHC class 1 molecules. The TISI
Table 1 Human cell lines in this study
Cells HLA–A24 p53 status2 p 53
Expression1 Accumulation3
TISI + WT4 –
C1R – pmR273 to H5 +
C1RA24 + pmR273 to H +
PC9 + pmR248 to Q +
HT 29 + pmR 273 to H +
MKN 45 + WT –
1HLA–A24 expression was determined serologically.
2Based on sequence analysis of reverse transcription PCR products
corresponding to exons 5~8.
3p53 protein overexpression was estimated by immunocytochemistry.
4WT, wild type
5pm, point mutation1054 Y Umano et al 
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cells were not treated. Adherent target cells were detached from
tissue culture flasks with trypsin-EDTA. All cells were labelled with
200 m Ci of 51Cr (Daiichi Kagaku Yakuhin, Tokyo, Japan) per 3 ´
106 cells for 1 h at 37˚C. Peptide-pulsed targets were prepared by
incubating the cells at 5 ´ 105 cells ml–1 with 10 mgm l –1 of the
peptide for 16 h at 37˚C. Target cells were washed by centrifugation
and mixed with effectors in a final volume of 0.2 ml in round-
bottom microtitre plates. The plates were centrifuged (2 min at 400
g) to increase cell-to-cell contact and placed in a CO2 incubator at
37˚C. After 4 h of incubation, 0.1 ml of the supernatant was
collected from each well and radioactivity was determined in a
gamma counter. To minimize non-specific lysis due to NK-like
effectors, the 10–30 fold excess of unlabelled K562 cells were
added. The MHC restriction was examined by testing the inhibition
of the cytotoxicity by anti HLA-class I MAbs W6/32 and anti HLA-
class II MAbs L243 and anti CD8 (Immunotec, Marseille, France).
Cold target inhibition experiments utilized using unlabelled C1R
cells and C1RA24 cells for completion for the recognition of 51Cr-
labelled HT29 tumour cells. 
The percentage of specific cytotoxicity was determined by
calculating the percentage of specific 51Cr-release by the following
formula: [(cpm of the test sample release – cpm of the spontaneous
release)/(cpm of the maximum release – cpm of the spontaneous
release)] ´ 100. The spontaneous release was determined by incu-
bating the target cells alone in the absence of effectors, and the
maximum release was obtained by incubating the targets with 1 N
HCl. All determinants were done in triplicate, and the standard
deviation error was consistently below 10% of the mean value
(Nukaya et al, 1999). 
Procedure of CTL expansion 
To obtain sufficient cell numbers for detailed characterization, CTL
lines were expanded in tissue cultures following methods similar to
the ones described by Walter et al (Walter, 1995; Salgauer et al,
1996; Nukaya et al, 1999). A total of 5 ´ 104 CTL were resuspended
in 25 ml of RPMI/5% HS with 25 ´ 106 irradiated (3300 rads)
PBMC and 5 ´ 106 irradiated (8000 rads) Epstein–Barr virus-trans-
formed b-lymphoblastoid cell line EHM cells (HLA-A3/3) in the
presence of 30 ng ml–1 of anti-CD3 MAb. One day after initiating
the cultures, 120 IU ml–1 of IL-2 was added to the cultures. The
cultures were fed with fresh RPMI/5% HS containing 30 IU ml–1 of
IL-2 on days 5, 8 and 11 and were split if the T-cell concentration
reached numbers >1.5 ´ 106 ml–1. On average, approximately 1–2 ´
107 CTLs were obtained by days 12–14. 
RESULTS 
HLA-A24 binding peptides from the murine p53
cytotoxic peptides 
To identify the potential epitope peptides of murine p53, the
sequence of murine p53 were examined for the presence of
specific MHC binding motifs for the H-2Kd and H-2Kb as exam-
ined for specific HLA-A alleles (Celis et al, 1994). 3 peptides were
selected based on the high-binding motifs as shown in Table 2, that
is, p53-137 (amino acids, 137-148) (Yaruck et al, 1993), p53-161
(161-169) (Vierboom et al, 1997), and p53–235 (235-243)
(Mayordomo et al, 1996). These peptides were synthesized and
their binding affinities were analysed by HLA-A24 peptide-
binding assay, using C1R-A24 cells. 
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Figure 1 Cytotoxic activity of CTL against peptide pulsed target cells. The
CTL line (p53-161-41) expanded after 4 cycles of restimulations with
peptides were tested for their cytotoxic activity. The recognition of peptide
(p53-161) pulsed TISI by the CTL. l, TISI pulsed with peptide (p53-161); 
l l, TISI without peptide 
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Figure 2 Cytotoxic activity against the various tumour cell lines by the CTL
line (p53-161-41). The cytotoxic activity of the effectors was assessed
against HT29 (colon carcinoma cell line, HLA-A24+, P53+), PC9 (lung
adenocarcinoma cell line, HLA-A24+, p53+), MKN45 (gastric carcinoma cell
line, HLA-A24+, P53-), at various E/T ratios 
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Figure 3 Inhibition of specific cytotoxic activity of the CTL line (p53-161-41)
by MAbs. 51Cr labelled HT29 tumour cells (HLA-A24+, p53+) were
preincubated with anti-HLA class I MAb or anti-HLA class II MAb, or the
CTLs were preincubated with anti-CD8 MAb for 1 h at room temperature.
After the incubations, effectors and targets were mixed at an E/T ratio of 20.
The cytotoxic activity was determined after 4 h incubation at 37˚C Generation of cytotoxic T cell responses 1055
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The C1R-A24 cell was incubated in the presence of 20 mgm l –1
of peptide for 2 h, stained with W6/32, the HLA class I specific
antibody, and analysed with flowcytometry. Expression level of
the MHC class I molecules was significantly higher than the nega-
tive control when p53-137 or p53-161 was pulsed (142 of mean
channels in the p53-161 peptide pulsed cells, 115 in the p53-137,
whereas 100 in the non peptide-pulsed cells). These results indi-
cate that 2 predicted peptides had HLA-A24 binding affinities. 
CTL induction 
The p53-161 and p53-137 peptides were studied for their capacity
to induce CTL in vitro. To examine this question, PBMCs from 6
HLA-A24+ healthy donors were stimulated using DCs pulsed with
synthetic peptides. The p53-161 peptide induced tumour-specific
CTL in 2 of the 4 donors. However, the p53-137 peptide did not
induce tumour-specific CTL. After 4 rounds of restimulation,
these CTLs that lysed peptide–pulsed target cells were expanded
using anti-CD3 MAb and a mixture of feeder cells for further
analysis. Peptide specific CTL responses were measured in a 4 h
51Cr releasing assay (CRA) using peptide-pulsed TISI cells as
targets. As shown in Figure 1, the CTL raised against p53-161
(line 41) efficiently lysed TISI cells only when they were pulsed
with p53-161 peptide. Furthermore, the p53-specific CTL lines
lysed the various cell lines which have p53 overexpression with
HLA-A24. The tumour lines, pretreated with 100 U ml–1 of IFNg
for 48 h, and non-labelled (cold) K562 cells were added to target
populations. HT29 (colon carcinoma, p53+, HLA-A24+), PC9
(lung adenocarcinoma, p53+, HLA-A24+) cells were significantly
lysed by the bulk CTL line 41, but MKN45 (gastric carcinoma,
p53–, HLA-A24+) cells were scarcely lysed (Figure 2). 
Characterization of the established CTLs 
To examine the characteristics of CTL lines raised against p53
peptide, MAbs against HLA class I MAb, HLA class II MAb, CD8
were tested for their capacity to inhibit the cytotoxic activity. The
cytotoxicity of CTL against the HT29 targets was significantly
reduced when anti class I and anti CD8 MAb were used, indicating
that the CTL lines recognize the p53 derived peptide in an HLA
class I restricted manner (Figure 3). Furthermore, the CTL lysed
C1R-A24 (p53+, HLA-A*2402 transfectant) cells, but not their
parent cell lines C1R (p53+, HLA A, B, C null cell) (Figure 4).
These results clearly indicate that the cytotoxic activity of the
CTLs is HLA-A*2402 in a restricted manner. Cold target inhibi-
tion experiments were performed using unlabelled C1R cells and
C1R-A24 cells to examine the specificity of CTL recognizing
HT29 tumour cells. The cytotoxicity against the HT29 cells was
suppressed with the cold C1R-A24 cells but not with C1R cells
(Figure 5). Thus, these results strongly suggest that the CTL lines
raised against p53-161 recognize p53-derived epitopes in 
HLA-A*2402 restricted fashion. 
DISCUSSION 
Tumour antigens, which are specifically presented by a class I
MHC molecules on the multiple types of tumours, are very good
candidates for cancer vaccine (Harris, 1996). However, most of
the TAAs currently available are expressed on specific tumour
types (Salgaller et al, 1996; Lee et al, 1999), and most of the
epitope peptides identified are restricted to HLA-A2 allele
(Butterfield et al, 1999; Vissers et al, 1999). This situation limits
the broad applicability of this approach. To improve the situa-
tion, efforts have been made to identify TAAs expressed in
multiple cell types (van den Burg et al, 1995; Tanaka et al, 1997;
Fujie et al, 1999; Kikuchi et al, 1999; Oiso et al, 1999). As the
same time, new tumour antigenic peptides restricted to other
HLA class I alleles have been explored (van den Burg et al,
1996; Nestle et al, 1998; Maric and Liu, 1999; Wang et al, 1999;
Yang et al, 1999). 
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Figure 4 HLA-A*2402 restricted cytotoxic activity by the CTL line (p53-161-
41). The cytotoxicity of the CTL was tested by 4 h CRA at various E/T ratios.
Target cells were C1R (p53+, HLA-A,B,C null cell), and C1R-A24 (p53+,
HLA-A*2402 transfectant) 
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Figure 5 Cold target inhibition assay with CTL line (p53-161-41) at 50 of
E/T ratio. Hot target was HT29 (p53+, HLA-A*2402). Cold targets were C1R
(p53+, HLA-A,B,C negative) or C1RA24 (p53+, HLA-A*2402) 
Table 2 Peptide prediction from murine p53 to human p53
Murine p53 Human p53
134–145 137–148
LAKTCPVQLWVS X‡XXXXXXXXXXD
(p53–137)
158–166 161–169
AIYKKSQHM XXXQXXXX
(p53–161)
232–240 235–243
KYMCNSSCM NXXXXXXXX
(p53–235)
X*: same amino acids between murine p53 and human p53.1056 Y Umano et al 
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Mutant p53 is expressed in 50% of malignant tumours.
Especially gastrointestinal carcinomas, which are the common
cancers in the Asian region, mutation of p53 is observed more
frequently when compared with that observed in tumours of other
types. The spectrum of p53 mutations is very wide and variable
(Harris, 1996). However, most mutation in p53 is a single base
missense-mutation confirmed in specific regions. Thus, some of
the wild-type epitopes outside of the area are maintained in many
cases. Wild-type p53 may be ignored by the immune system due to
insufficient amounts and extremely short t1/2 (Gnjatic et al, 1998).
Mutated p53 would become immunogenic due to the stabilization
and the accumulation in tumour cells. Therefore, the epitopes
found in the conserved area of the wild-type p53 could serve as
immunologic targets in various tumour types. 
The idea that p53 can serve as a target for immunotherapy has
been explored in the past (Zhou et al, 1999; Hernandez et al,
2000), and antigenic p53 peptides restricted by HLA-A2 have
been described. However, the antigenic peptides restricted to
HLA-A24 allele, most of which (90%) is HLA-A*2402 subtype
and frequency (60%) expressed in Asians including Japanese
(Nukaya et al, 1999). Thus, we have tried to identify a new p53
epitope peptide presented by HLA-A24. 
In this study, we obtained the evidence that p53-161, nonamer
peptide derived from wild-type p53, induces CTL in vitro. The
induced CTL line showed specific cytotoxicity not only against the
peptide-pulsed target cells but also against HLA-A24-positive
adenocarcinoma cell lines overexpressing p53. Because the wild-
type p53 is normally ignored by the immune system due to its short
half-life, this response is not so much recognition of endogenously
processed with wild-type p53 in MKN45 cell or TISI cell as bulk
CTL response. However, Ropke et al, reported that the accumula-
tion of mutated p53 protein was not absolute requirement for
killing by p53-specific CTL (Ropke et al, 1996). The relation
between presentation of p53 epitope and recognition by p53
specific CTL still remains to be examined. Furthermore, these
CTLs kill targets in an HLA-A24 restricted manner. These results
suggest that the p53–161 peptide is one of p53 epitope peptides
restricted to HLA-A24. 
The P53–161 peptide (AIYKQSQHM) derived from human
wild-type p53 was predicted from the epitope (AIYKKSQHM;
amino acid 158–166) derived from mouse wild-type p53. The
CTL, generated in p53-deficient mice and recognizing this peptide
presented on H-2Kb molecule was also capable of preventing the
outgrowth of p53-overexpressed tumours in immunocompetent
p53 (+/+) C57BL/6 mice (Vierboom et al, 1997). Typical HLA-
A24 binding motifs have Tyr or Trp at position 2 and Phe, Leu or
Ileu at position 9 of a nonamer peptide. Interestingly, p53-161 has
Tyr at position 3, and Met, of which affinity is lower than Phe, Leu
and Ileu, at position 9 (Kubo et al, 1994). These characteristics
lead to low binding affinity of p53-161 peptide for HLA-A24
molecules. It is possible that other peptides with which high
affinity could be expressed at high levels on the cell surface during
initial T cell education may be deleted from the T-cell repertoire.
Lower binding or subdominant determinants could have escaped
this process for tolerance induction (van den Burg et al, 1995).
Similar to some of the other peptide epitopes of TAAs (Solgaller
et al, 1996), p53–161 has only one anchor residue and weak
binding affinity to HLA-A24. It has been very difficult to treat the
advanced and metastatic cancers with any exiting therapy including
surgery, chemotherapy and radiotherapy. As the mutated p53 accu-
mulates in most of the metastatic tumour cells, and is associated
with the resistance to chemotherapy and radiotherapy, a p53-
peptide-based immunotherapy could be helpful for patients with
advanced cancer. Furthermore, immunization with a combination
of other antigens including CEA and HER2/neu might lead to a
successful outcome. 
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